Mark Emberton on Focal therapy for men with intermediate risk prostate cancer and a solitary lesion should be standard of care - STOP 6

Focal therapy for men with intermediate risk prostate cancer and a solitary lesion should be standard of care  (STOP 6)

Biography:
Mark Emberton, MD, FRCS is a Professor of Interventional Oncology at the University College London. He is an Honorary Consultant Urologist at University College Hospitals NHS Foundation Trust and Founding Pioneer of The Charity Prostate Cancer UK. Dr. Emberton was appointed Dean of UCL Faculty of Medical Sciences in 2015. Dr. Emberton’s clinical research is aimed at improving the diagnostic and risk stratification tools and treatment strategies for prostate cancer (PCa); he specializes in the implementation of new imaging techniques, nanotechnologies, bio-engineering materials and non-invasive treatment approaches, such as high intensity focused ultrasound and photo-dynamic therapy.